Plasma levels of intermedin (adrenomedullin-2) in healthy human volunteers and patients with heart failure

Peptides
David BellMark T Harbinson

Abstract

Intermedin/adrenomedullin-2 (IMD) is a member of the adrenomedullin/CGRP peptide family. Less is known about the distribution of IMD than for other family members within the mammalian cardiovascular system, particularly in humans. The aim was to evaluate plasma IMD levels in healthy subjects and patients with chronic heart failure. IMD and its precursor fragments, preproIMD(25-56) and preproIMD(57-92), were measured by radioimmunoassay in 75 healthy subjects and levels of IMD were also compared to those of adrenomedullin (AM) and mid-region proadrenomedullin(45-92) (MRproAM(45-92)) in 19 patients with systolic heart failure (LVEF<45%). In healthy subjects, plasma levels (mean+SE) of IMD (6.3+0.6 pg ml(-1)) were lower than, but correlated with those of AM (25.8+1.8 pg ml(-1); r=0.49, p<0.001). Plasma preproIMD(25-56) (39.6+3.1 pg ml(-1)), preproIMD(57-92) (25.9+3.8 pg ml(-1)) and MRproAM(45-92) (200.2+6.7 pg ml(-1)) were greater than their respective bioactive peptides. IMD levels correlated positively with BMI but not age, and were elevated in heart failure (9.8+1.3 pg ml(-1), p<0.05), similarly to MRproAM(45-92) (329.5+41.9 pg ml(-1), p<0.001) and AM (56.8+10.9 pg ml(-1), p<0.01). IMD levels were greater in heart failure patie...Continue Reading

References

Mar 10, 1998·Endocrinology·Y IsumiN Minamino
Jan 30, 1999·The Journal of Endocrinology·N HirayamaT Eto
Mar 14, 2000·Life Sciences·M Jougasaki, J C Burnett
Sep 14, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Claudio LetiziaEmilio D' Erasmo
Dec 18, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Johji KatoTanenao Eto
Aug 24, 2004·European Journal of Pharmacology·Yoshihide FujisawaYouichi Abe
Mar 25, 2005·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·C LetiziaU Di Mario
Mar 10, 2007·Peptides·Ryo MorimotoKazuhiro Takahashi
Sep 1, 2007·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·David BellBarbara J McDermott
May 6, 2008·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·David BellBarbara J McDermott
Mar 31, 2009·European Journal of Heart Failure·Michele EmdinAldo Clerico
Mar 11, 2010·European Journal of Heart Failure·Stephan von HaehlingStefan D Anker
Mar 17, 2010·Pacing and Clinical Electrophysiology : PACE·Maria-Aurora MoralesSilvia Del Ry
Mar 19, 2013·Peptides·Zhengbing LvBiying Hong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.